Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-12-06
1998-07-14
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514813, A61K 3800
Patent
active
057804338
ABSTRACT:
Neuronal nicotinic acetylcholine receptors (nAChRs) are believed to mediate nicotine addiction. In addition, stimulation of nAChRs modulates release of neurotransmitters including dopamine, norepinephrine and serotonin. Thus, pharmacological manipulation of nicotinic receptors has implications for a wide variety of disorders including psychotic, mood, movement and cognitive. For most nAChRs, there are no subtype selective ligands. However, .alpha.-conotoxin MII, a small peptide from the carnivorous marine snail Conus magus, was recently isolated. This peptide has been shown to be a specific antagonist for .alpha.3.beta.2 nicotinic receptors. The peptide potently blocks part, but not all, of nicotine-stimulated dopamine release from rat brain striatal synaptosomes. In contrast it has no effect on potassium stimulated dopamine release. Other .alpha.-conotoxins specifically target distinct neuronal nAChR subtypes. .alpha.-Conotoxins thus represent new lead compounds for CNS disorders.
REFERENCES:
patent: 5595972 (1997-01-01), Olivera et al.
patent: 5633347 (1997-05-01), Olivera et al.
Tennant et al. NIDA Res. Monogr., 49, 239, 1984.
Tennant et al, NIDA Res. Monogr, 55, 291-297, 1984.
Rose et al, Pharmacol. Bioch. & Behav, 32, 933-938, 1989.
Rose et al, Clin. Pharmacol. & Therapeutics, 56(1), 86-98, Jul. 1994.
Benwell et al, Br. J. Pharmacol, 117, 743-749, Feb. 1996.
Corrigall et al, Psychopharmacol., 99, 473-478, 1989.
Glick et al, Nature, 227, 969-970, 1970.
Stolerman et al, Psycho Pharmacologia, 28, 247-259, 1973.
Harvey et al, 26 Annual Meeting of Society for Neurosc. 22 (1-3) p. 1259, Nov. 1996.
Cartier et al, J. Biol. Chem. 271 (13) pp. 7522-7528, Mar. 29, 1996.
Corrigall et al, Psychopharmacology, 104, 171-176, 1991.
Corrigall et al, Brain Research, 653, 278-284, 1994.
Kulak Jennifer M.
McIntosh J. Michael
Olivera Baldomero M.
Yoshikami Doju
Cook Rebecca
University of Utah Research Foundation
LandOfFree
Use of .alpha.-conotoxin MII to treat disorders resulting from n does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of .alpha.-conotoxin MII to treat disorders resulting from n, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of .alpha.-conotoxin MII to treat disorders resulting from n will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1881755